Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

OCTIMET Oncology

Request full access

Provides differentiation both within the current treatment paradigms and from competitor agents using biomarker defined intelligent patient selection

Ghent, BelgiumFounded 2016Biotech & Life Sciences

About OCTIMET Oncology

OCTIMET is a biotechnology company focused on developing highly selective anti-tumor molecules, particularly cMET inhibitors, to treat cancer. The company employs innovative patient selection and pharmacodynamic biomarker-based strategies to enhance the efficacy of its treatments. OCTIMET operates in the oncology market, targeting pharmaceutical companies and healthcare providers as its primary clients. The business model revolves around drug discovery and development, with revenue generated through partnerships, licensing agreements, and eventual drug sales. The company has a robust pipeline, including its lead candidate OMO-1, which has shown promising results in clinical trials. OCTIMET's team comprises seasoned professionals with extensive experience in global pharma and oncology drug development, ensuring a high level of expertise and innovation in their approach.

Source: Dealroom company data

At a glance

Status
Operational
Employees
1
Open positions
None listed
Dealroom signal
55.9/100
Industry
Health
Sub-industry
BioTechnology
Sector
Biotechnology, Oncology, Drug Development, Immersive Technologies, Sustainable Development Goals, Biotech and Pharma, Climate Tech, Woman Founder, DT and LS
Technology
Virtual Reality
Business model
SaaS
Client focus
B2B

Funding history

1 recorded event

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SERIES A✓Equity / VC Jan 2017 $12M $50M Omnes Capital · V-Bio Ventures · FundPlus —
Showing the latest 1 of 1 recorded eventsBook a demo for the full funding history →

Financials

Revenue, earnings and profit over time

Revenue, earnings and other financial measures where available. Years marked “E” are estimates.

YearEBITDAMarginProfitMargin
2026 — —
2025 — —
2024 — —
2023 — —
2022 — —
2021 — —
2020 — —
Company filings, research estimates and Dealroom dataBook a demo for the full financial model →

Growth signals

OCTIMET Oncology website traffic

Latest recorded traffic for OCTIMET Oncology is 260 monthly website visits, down 16.1% over the last three months. OCTIMET Oncology's team grew 0% over the past year.

Latest monthly visits260 3-month web change-16.1% 1-year team growth0%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

OCTIMET Oncology in the Ghent ecosystem

Live from Dealroom

The OCTIMET Oncology office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

4 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A3 investors entered at this stage

  • V-Bio Ventures
  • FundPlus
  • Omnes Capital

Other known investors1 additional known investor

  • Droia Oncology Ventures
Team profiled 9 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 5 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
1 countries with
team presence
🇧🇪 Belgium100%
1 country shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about OCTIMET Oncology on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See OCTIMET Oncology’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.